Understanding how loss of the Y-chromosome affects HIV-1 latency
Official title: Loss of Y-chromosome as a driver of HIV-1 latency
Funded at University of Alabama at Birmingham · NIH-10882257 · Data updated 2026-11-12
This study is looking at how changes in certain immune cells might help the HIV virus hide in the body even when people are getting treatment, and it aims to find new ways to tackle this problem for those living with HIV.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | August 16, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $424,254 |
| NIH project number | 1R56AI179301-01 |
| Project ID | NIH-10882257 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are male patients living with HIV-1 who have experienced latency in their infection.
✕Less likely to help
Patients who are female or do not have HIV-1 may not benefit from this research.
What this research studies
This research investigates how the loss of the Y-chromosome in T cells may contribute to the persistence of HIV-1 infection in the body. By examining the genetic and cellular changes in latently infected T cells, the study aims to uncover the mechanisms that allow HIV-1 to remain dormant despite treatment. The researchers will analyze various T cell types to determine how these chromosomal changes affect the behavior and reactivation of the virus. This could lead to new insights into HIV-1 latency and potential therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for targeting and eliminating latent HIV-1 reservoirs in patients.
How similar studies have gone: While the specific approach of examining Y-chromosome loss in relation to HIV-1 latency is novel, similar studies have shown promise in understanding HIV-1 persistence.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Kutsch, Olaf — University of Alabama at Birmingham
- Study coordinator: Kutsch, Olaf
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.